サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1750781

統合失調症治療薬の市場規模、シェア、動向分析レポート：薬剤クラス別、投与経路別、流通チャネル別、地域別、セグメント予測、2025年～2030年

Schizophrenia Drugs Market Size, Share & Trends Analysis Report By Drug Class (Second- generation Antipsychotics, Third-Generation Antipsychotics), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
統合失調症治療薬の市場規模、シェア、動向分析レポート：薬剤クラス別、投与経路別、流通チャネル別、地域別、セグメント予測、2025年～2030年
出版日: 2025年05月09日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

統合失調症治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の統合失調症治療薬の市場規模は2030年までに112億米ドルに達し、2025年から2030年にかけてCAGR5.6%で成長すると予測されています。

統合失調症市場は、ドラッグデリバリー技術の向上、長時間作用型注射剤（LAI）の入手可能性、治療を求める患者の増加などにより、総体的に牽引されると予測されています。新規薬剤の普及を後押しする主な特徴は、作用発現の速さ、患者へのアクセスのしやすさ、効率性、患者のコンプライアンスの高さと考えられています。

統合失調症は、患者やその家族、社会全体に大きな負担を強いています。精神疾患、特に統合失調症に対する患者や医師の意識の高まりは、新薬の市場浸透を促進すると思われます。現在、第2世代と第3世代の抗精神病薬が大きな市場シェアを占めています。臨床試験中のパイプライン医薬品は、セロトニン受容体やドーパミン受容体の特定のサブタイプをブロックすることで、症状を最小限に抑え、ドーパミンレベルの上昇を調整し、さらに記憶力を向上させることを意図しています。

統合失調症市場の成長は、主にIntra-Cellular TherapiesのITI-007やAlkermesのALKS-3831のような、陰性症状の治療を目的とした後期段階のパイプライン製品の登場によって牽引されると予想されますが、統合失調症治療領域には大きなアンメットニーズが存在します。しかし、統合失調症治療の分野では大きなアンメットニーズがあります。正確な疾患メカニズムに関する理解が不十分なため、画期的な治療薬の発見が妨げられているのです。したがって、この衰弱性疾患の治療にはドラッグデリバリー技術の革新が必要です。

統合失調症治療薬市場レポートハイライト

  • 第2世代抗精神病薬が2024年の市場売上シェアで73.05%と最大となりました。統合失調症治療薬市場における第二世代抗精神病薬の需要は、第一世代抗精神病薬に比べて安全性と有効性のプロファイルが改善されていることから増加しています。
  • 注射用抗精神病薬治療セグメントは2024年に最大の市場売上シェアを占めました。注射用抗精神病薬の需要は、この疾患に関連するいくつかの課題に対処できることから増加傾向にあります。注射剤、特に長時間作用型注射剤（LAI）は安定した薬物放出が可能であるため、治療薬レベルの維持に役立ち、経口薬によく見られる飲み忘れによる再発リスクを軽減することができます。
  • 2024年には、病院薬局セグメントが最大の市場売上シェアを占めました。病院薬局は、複雑な投薬レジメンの管理や副作用のモニタリングなど、総合的なケアを提供するのに適した立場にあります。
  • 北米の統合失調症治療薬市場は、2024年に38.65%の最大市場売上シェアを占めました。これは、統合失調症および関連する精神疾患の認知度と診断率の上昇に起因しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 統合失調症治療薬市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 統合失調症治療薬市場分析ツール
    • 業界分析-ポーターのファイブフォース分析
    • PESTEL分析
    • 価格分析
    • パイプライン分析

第4章 統合失調症治療薬市場：薬剤クラスの推定・動向分析

  • 世界の統合失調症治療薬市場：薬剤クラスダッシュボード
  • 世界の統合失調症治療薬市場：薬物クラスの変動分析
  • 世界の統合失調症治療薬市場：クラス別、収益別
  • 第二世代抗精神病薬
  • 第三世代抗精神病薬

第5章 統合失調症治療薬市場：投与経路の推定・動向分析

  • 世界の統合失調症治療薬市場：投与経路ダッシュボード
  • 世界の統合失調症治療薬市場：投与経路の変動分析
  • 世界の統合失調症治療薬市場：投与経路別、収益別
  • 経口抗精神病薬
  • 注射用抗精神病薬

第6章 統合失調症治療薬市場：流通チャネルの推定・動向分析

  • 世界の統合失調症治療薬市場：流通チャネルダッシュボード
  • 世界の統合失調症治療薬市場：流通チャネル変動分析
  • 世界の統合失調症治療薬市場：流通チャネル別、収益別
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

第7章 統合失調症治療薬市場：地域推定・動向分析、薬剤クラス別、流通チャネル別、投与経路別

  • 地域ダッシュボード
  • 市場規模、予測、動向分析、2018年～2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 最近の動向と影響分析：主要市場参入企業別
  • 企業/競合の分類
  • ベンダー情勢
    • 主要販売代理店・チャネルパートナーのリスト
    • 主要顧客
    • 主要企業市場シェア分析、2024年
    • Johnson &Johnson Services, Inc.
    • Bristol-Myers Squibb Company/Otsuka Holdings Co., Ltd.
    • Sumitomo Pharma Co., Ltd.
    • Eli Lilly and Company
    • Alkermes
    • VANDA PHARMACEUTICALS
    • AstraZeneca
    • AbbVie Inc.
    • Pfizer Inc.
    • H. Lundbeck A/S
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 3 North America Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 4 North America Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 U.S. Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 6 U.S. Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 7 U.S. Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 Canada Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 9 Canada Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 Canada Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 Mexico Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 12 Mexico Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 13 Mexico Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Europe Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 15 Europe Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 16 Europe Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Germany Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 18 Germany Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 19 Germany Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 UK Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 21 UK Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 UK Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 France Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 24 France Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 25 France Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 Italy Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 27 Italy Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 28 Italy Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 Spain Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 30 Spain Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 31 Spain Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 China Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 36 China Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 37 China Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Japan Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 39 Japan Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 40 Japan Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 India Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 42 India Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 India Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 South Korea Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 45 South Korea Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 South Korea Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Latin America Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 48 Latin America Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 49 Latin America Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 50 Brazil Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 51 Brazil Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 52 Brazil Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 MEA Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 54 MEA Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 55 MEA Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 South Africa Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 57 South Africa Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 South Africa Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 UAE Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 63 UAE Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 64 UAE Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 67 Kuwait Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Schizophrenia Drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug Class and Route of Administration segment snapshot
  • Fig. 10 Route of Administration segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Pharmaceutical market, (USD Billion)
  • Fig. 13 Market dynamics
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Schizophrenia Drugs market: Drug Class Outlook and key takeaways
  • Fig. 17 Schizophrenia Drugs market: Drug Class movement analysis
  • Fig. 18 Second-Generation Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Risperdal (Risperidone) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Invega (Paliperidone) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Zyprexa (Olanzapine) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Geodon (Ziprasidone) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Seroquel (Quetiapine) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Latuda (Lurasidone) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Aristada (Aripiprazole Lauroxil) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Fanapt (Iloperidone) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Saphris (Asenapine) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Vraylar (Cariprazine) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Third-Generation Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Abilify (Aripiprazole) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Schizophrenia Drugs market: Route of Administration Outlook and key takeaways
  • Fig. 33 Schizophrenia Drugs market: Route of Administration movement analysis
  • Fig. 34 Oral Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Injectable Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Schizophrenia Drugs market: Distribution Channel Outlook and key takeaways
  • Fig. 37 Schizophrenia Drugs market: Distribution Channel movement analysis
  • Fig. 38 Hospital Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Retail Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Online Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Schizophrenia Drugs market revenue, by region, 2024 & 2030, (USD Million)
  • Fig. 43 Regional marketplace: Key takeaways
  • Fig. 44 North America schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Target disease prevalence
  • Fig. 47 U.S. schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Target disease prevalence
  • Fig. 50 Canada schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Mexico schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Target disease prevalence
  • Fig. 54 Europe schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Target disease prevalence
  • Fig. 57 UK schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Target disease prevalence
  • Fig. 60 Germany schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Target disease prevalence
  • Fig. 63 France schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Target disease prevalence
  • Fig. 66 Spain schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Target disease prevalence
  • Fig. 69 Italy schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Target disease prevalence
  • Fig. 72 Denmark schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Target disease prevalence
  • Fig. 75 Sweden schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Target disease prevalence
  • Fig. 78 Norway schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Rest of Europe schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Asia Pacific schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Target disease prevalence
  • Fig. 83 Japan schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Target disease prevalence
  • Fig. 86 China schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Target disease prevalence
  • Fig. 89 India schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 Target disease prevalence
  • Fig. 92 Australia schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 Thailand schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 South Korea schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Rest of Asia Pacific schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Latin America schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Key country dynamics
  • Fig. 100 Target disease prevalence
  • Fig. 101 Brazil schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Key country dynamics
  • Fig. 103 Target disease prevalence
  • Fig. 104 Argentina schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Rest of Latin America schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 MEA schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Key country dynamics
  • Fig. 108 Target disease prevalence
  • Fig. 109 South Africa schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 Key country dynamics
  • Fig. 111 Target disease prevalence
  • Fig. 112 Saudi Arabia schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Key country dynamics
  • Fig. 114 Target disease prevalence
  • Fig. 115 UAE schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 116 Key country dynamics
  • Fig. 117 Target disease prevalence
  • Fig. 118 Kuwait schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 Rest of MEA schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-2-68038-222-8

Schizophrenia Drugs Market Growth & Trends:

The global schizophrenia drugs market size is expected to reach USD 11.20 billion by 2030, registering to grow at a CAGR of 5.6% from 2025 to 2030 according to a new report by Grand View Research, Inc. The schizophrenia market is anticipated to be collectively driven by improved drug delivery technologies, availability of Long-Acting Injectables (LAIs) and increase in patients seeking treatment. The major features assisting uptake of novel drugs would be fast onset of action, accessibility to patients, efficiency and high patient compliance.

Schizophrenia imposes substantial burden on patients, their families and the overall society. Increasing awareness among patients and physicians in the field of mental health, particularly schizophrenia is likely to increase the penetration of these drugs in the market. Currently, second and third-generation antipsychotics capture significant market share. Pipeline drugs, undergoing clinical trials intend to block specific subtypes of serotonin and dopamine receptors which would help minimize the symptoms, modulate increased dopamine levels and further improve memory.

The growth in schizophrenia market is anticipated to be primarily driven by the arrival of late-stage pipeline products, such as Intra-Cellular Therapies' ITI-007 and Alkermes' ALKS-3831 which are directed towards the treatment of negative symptoms; however, there are significant unmet needs in the schizophrenia treatment space. Poor understanding about the exact disease mechanism remains, preventing the discovery of a therapeutic breakthrough. Hence, there is a need for innovation in drug delivery technologies for the treatment of this debilitating disorder.

Schizophrenia Drugs Market Report Highlights:

  • The second-generation-antipsychotics held the largest market revenue share of 73.05% in 2024. The demand for second-generation antipsychotics in the schizophrenia drugs market is rising due to their improved safety and efficacy profiles compared to first-generation antipsychotics.
  • The injectable antipsychotics treatment segment held the largest market revenue share in 2024. The demand for injectable antipsychotics is on the rise due to their ability to address several challenges associated with the condition. Injectable formulations, particularly long-acting injectables (LAIs), provide a steady release of medication, which helps maintain therapeutic drug levels and reduces the risk of relapse due to missed doses-a common issue with oral medications.
  • The hospital pharmacies segment held the largest market revenue share in 2024. Hospital pharmacies are well-positioned to provide comprehensive care, including managing complex medication regimens and monitoring side effects, which are critical for this condition.
  • North America schizophrenia drugs market held the largest market revenue share of 38.65% in 2024. It is attributable to the rising awareness and diagnosis rates of schizophrenia and related mental health disorders.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Class
    • 1.2.2. Treatment
    • 1.2.3. Treatment
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class and Route of Administration Outlook
    • 2.2.2. Distribution Channel Outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Schizophrenia Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Schizophrenia Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Pipeline Analysis
      • 3.3.4.1. Phase 1
      • 3.3.4.2. Phase 2
      • 3.3.4.3. Phase 2

Chapter 4. Schizophrenia Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1. Global Schizophrenia Drugs Market: Drug Class Dashboard
  • 4.2. Global Schizophrenia Drugs Market: Drug Class Movement Analysis
  • 4.3. Global Schizophrenia Drugs Market by Class, Revenue
  • 4.4. Second-Generation Antipsychotics
    • 4.4.1. Second-Generation Antipsychotics market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1. Risperdal (Risperidone)
        • 4.4.1.1.1. Risperdal (Risperidone) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Invega (Paliperidone)
        • 4.4.1.2.1. Invega (Paliperidone) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Zyprexa (Olanzapine)
        • 4.4.1.3.1. Zyprexa (Olanzapine) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Geodon (Ziprasidone)
        • 4.4.1.4.1. Geodon (Ziprasidone) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Seroquel (Quetiapine)
        • 4.4.1.5.1. Seroquel (Quetiapine) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.6. Latuda (Lurasidone)
        • 4.4.1.6.1. Latuda (Lurasidone) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.7. Aristada (Aripiprazole Lauroxil)
        • 4.4.1.7.1. Aristada (Aripiprazole Lauroxil) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.8. Fanapt (Iloperidone)
        • 4.4.1.8.1. Fanapt (Iloperidone) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.9. Vraylar (Cariprazine)
        • 4.4.1.9.1. Vraylar (Cariprazine) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Third-Generation Antipsychotics
    • 4.5.1. Schizophrenia Drugs market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Schizophrenia Drugs Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Global Schizophrenia Drugs Market: Route of Administration Dashboard
  • 5.2. Global Schizophrenia Drugs Market: Route of Administration Movement Analysis
  • 5.3. Global Schizophrenia Drugs Market by Route of Administration , Revenue
  • 5.4. Oral Antipsychotics
    • 5.4.1. Oral Antipsychotics market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Injectable Antipsychotics
    • 5.5.1. Injectable Antipsychotics market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Schizophrenia Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global Schizophrenia Drugs Market: Distribution Channel Dashboard
  • 6.2. Global Schizophrenia Drugs Market: Distribution Channel Movement Analysis
  • 6.3. Global Schizophrenia Drugs Market by Distribution Channel, Revenue
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Schizophrenia Drugs Market: Regional Estimates & Trend Analysis by Drug Class, Distribution Channel, and Route of Administration

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Johnson & Johnson Services, Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Class benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Bristol-Myers Squibb Company/ Otsuka Holdings Co., Ltd.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Class benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Sumitomo Pharma Co., Ltd.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Class benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Eli Lilly and Company
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Class benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Alkermes
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Class benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. VANDA PHARMACEUTICALS
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Class benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. AstraZeneca
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Class benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. AbbVie Inc.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Class benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Pfizer Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Class benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. H. Lundbeck A/S
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Class benchmarking
      • 8.3.13.4. Strategic initiatives